Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls "the patent cliff." The need for pharma to top up their ...

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a doctor’s office. Ikarovec’s IKAR-003 is currently in preclinical ...

After a strong open to the year, the public markets suffered a six-month drought that led to biotech’s tightest IPO window in years. 2025 began on an encouraging note for biopharma. In addition to the ...

A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on Monday, as investors poured cash into energy shares following the U.S.

In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year. Last year was challenging across the board. In a time that was expected to usher in some sort of recovery from ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...